Skip to main content
NCD 190.20 · version 2 · Laboratory NCD

NCD 190.20: Blood Glucose Testing

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.20

Benefit category
Diagnostic Laboratory Tests
Effective date
01/01/2005
Implemented 03/11/2005
Transmittal
Transmittal 28
Versions published
2
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
4,634 covered ICD-10
466 non-covered

TL;DR

NCD 190.20 sets Medicare's national policy for blood glucose testing under the benefit category "Diagnostic Laboratory Tests", effective 01/01/2005 and implemented 03/11/2005. Blood glucose values are often necessary for the management of patients with diabetes mellitus, where hyperglycemia and hypoglycemia are often present. They are also critical in the determination of control of blood glucose levels in the patient with impaired… As a laboratory NCD it carries a national ICD-10 edit list: 4,634 diagnosis codes support medical necessity and 466 are denied, applied automatically by every Medicare contractor to 3 procedure codes.

Item or service described

This policy is intended to apply to blood samples used to determine glucose levels. Blood glucose determination may be done using whole blood, serum or plasma. It may be sampled by capillary puncture, as in the fingerstick method, or by vein puncture or arterial sampling. The method for assay may be by color comparison of an indicator stick, by meter assay of whole blood or a filtrate of whole blood, using a device approved for home monitoring, or by using a laboratory assay system using serum or plasma. The convenience of the meter or stick color method allows a patient to have access to blood glucose values in less than a minute or so and has become a standard of care for control of blood glucose, even in the inpatient setting.

Indications and limitations of coverage

Indications

Blood glucose values are often necessary for the management of patients with diabetes mellitus, where hyperglycemia and hypoglycemia are often present. They are also critical in the determination of control of blood glucose levels in the patient with impaired fasting glucose (FPG 110-125 mg/dL), the patient with insulin resistance syndrome and/or carbohydrate intolerance (excessive rise in glucose following ingestion of glucose or glucose sources of food), in the patient with a hypoglycemia disorder such as nesidioblastosis or insulinoma, and in patients with a catabolic or malnutrition state. In addition to those conditions already listed, glucose testing may be medically necessary in patients with tuberculosis, unexplained chronic or recurrent infections, alcoholism, coronary artery disease (especially in women), or unexplained skin conditions (including pruritis, local skin infections, ulceration and gangrene without an established cause).

Many medical conditions may be a consequence of a sustained elevated or depressed glucose level. These include comas, seizures or epilepsy, confusion, abnormal hunger, abnormal weight loss or gain, and loss of sensation. Evaluation of glucose may also be indicated in patients on medications known to affect carbohydrate metabolism.

Effective January 1, 2005, the Medicare law expanded coverage to diabetic screening services. Some forms of blood glucose testing covered under this national coverage determination may be covered for screening purposes subject to specified frequencies. See 42 CFR 410.18 and section 90, chapter 18, of the Claims Processing Manual , for a full description of this screening benefit.

Limitations

Frequent home blood glucose testing by diabetic patients should be encouraged. In stable, non-hospitalized patients who are unable or unwilling to do home monitoring, it may be reasonable and necessary to measure quantitative blood glucose up to four times annually.

Depending upon the age of the patient, type of diabetes, degree of control, complications of diabetes, and other co-morbid conditions, more frequent testing than four times annually may be reasonable and necessary.

In some patients presenting with nonspecific signs, symptoms, or diseases not normally associated with disturbances in glucose metabolism, a single blood glucose test may be medically necessary. Repeat testing may not be indicated unless abnormal results are found or unless there is a change in clinical condition. If repeat testing is performed, a specific diagnosis code (e.g., diabetes) should be reported to support medical necessity. However, repeat testing may be indicated where results are normal in patients with conditions where there is a confirmed continuing risk of glucose metabolism abnormality (e.g., monitoring glucocorticoid therapy).

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.20 version 2. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 4,634 covered and 466 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

3 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.20
CodeCode set
82947CPT (descriptor licensed by AMA)
82948CPT (descriptor licensed by AMA)
82962CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 3 of the 3 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $3.28 to $5.04, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.20 edits, October 2026
CodeCLFS amountWith QWPricing
82947$3.93$3.93national payment amount
82948$5.04—national payment amount
82962$3.28—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 4,634 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.20 (sample)
ICD-10-CMDescriptionEffective
A15.0Tuberculosis of lung2015-10-01
A15.5Tuberculosis of larynx, trachea and bronchus2015-10-01
A22.1Pulmonary anthrax2015-10-01
A37.01Whooping cough due to Bordetella pertussis with pneumonia2015-10-01
A37.11Whooping cough due to Bordetella parapertussis with pneumonia2015-10-01
A37.81Whooping cough due to other Bordetella species with pneumonia2015-10-01
A37.91Whooping cough, unspecified species with pneumonia2015-10-01
A40.0Sepsis due to streptococcus, group A2015-10-01
A40.1Sepsis due to streptococcus, group B2015-10-01
A40.3Sepsis due to Streptococcus pneumoniae2015-10-01
A40.8Other streptococcal sepsis2015-10-01
A40.9Streptococcal sepsis, unspecified2015-10-01
A41.01Sepsis due to Methicillin susceptible Staphylococcus aureus2015-10-01
A41.02Sepsis due to Methicillin resistant Staphylococcus aureus2015-10-01
A41.1Sepsis due to other specified staphylococcus2015-10-01
A41.2Sepsis due to unspecified staphylococcus2015-10-01
A41.3Sepsis due to Hemophilus influenzae2015-10-01
A41.4Sepsis due to anaerobes2015-10-01
A41.50Gram-negative sepsis, unspecified2015-10-01
A41.51Sepsis due to Escherichia coli [E. coli]2015-10-01
A41.52Sepsis due to Pseudomonas2015-10-01
A41.53Sepsis due to Serratia2015-10-01
A41.54Sepsis due to Acinetobacter baumannii2023-10-01
A41.59Other Gram-negative sepsis2015-10-01
A41.81Sepsis due to Enterococcus2015-10-01
A41.89Other specified sepsis2015-10-01
A41.9Sepsis, unspecified organism2015-10-01
A42.7Actinomycotic sepsis2015-10-01
A48.1Legionnaires' disease2015-10-01
B25.0Cytomegaloviral pneumonitis2015-10-01
B25.2Cytomegaloviral pancreatitis2015-10-01
B37.2Candidiasis of skin and nail2015-10-01
B37.31Acute candidiasis of vulva and vagina2022-10-01
B37.32Chronic candidiasis of vulva and vagina2022-10-01
B44.0Invasive pulmonary aspergillosis2015-10-01
B48.8Other specified mycoses2015-10-01
B77.81Ascariasis pneumonia2015-10-01
B78.1Cutaneous strongyloidiasis2015-10-01
C25.4Malignant neoplasm of endocrine pancreas2015-10-01
C48.0Malignant neoplasm of retroperitoneum2015-10-01

466 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.20 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release changed this NCD's ICD-10-CM list: 3 codes added and 1 code removed against January 2026. CMS marked 6 rows of the list as changed in this release. A removed code stops counting for the edit after its term date; where the FY2027 ICD-10-CM update deleted the code, the replacement codes listed below are the ones to report from October 1, 2026.

ICD-10-CM codes added to NCD 190.20 in October 2026
ICD-10-CMFY2027 descriptionResult
M86.8X71Other osteomyelitis, right ankle and footcovered
M86.8X72Other osteomyelitis, left ankle and footcovered
M86.8X79Other osteomyelitis, unspecified ankle and footcovered
ICD-10-CM codes removed from NCD 190.20 in October 2026
ICD-10-CMDescriptionWasWhy
M86.8X7Other osteomyelitis, ankle and footcovereddeleted from ICD-10-CM; replaced by M86.8X71, M86.8X72, M86.8X79

Codes on this NCD's list by release: October 2025: 2,696 · January 2026: 2,808 · October 2026: 2,810. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Local policies that build on this NCD

2 active Local Coverage Determinations cite NCD 190.20 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

How MACs bill NCD 190.20

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 2 current articles in the Medicare Coverage Database name NCD 190.20, 2 of them with a covered ICD-10-CM list, from 2 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

Contractors with articles that implement NCD 190.20
ContractorArticles
Wellpoint FederalA58116
Wisconsin Physicians Service Insurance CorporationA58213

A58116: Billing and Coding: Implantable Continuous Glucose Monitors (I-CGM)

Billing and Coding, effective 2026-09-10 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

373 covered ICD-10-CM codes; 3 procedure codes: 0446T, 0447T, 0448T. Local policy: L38623 Implantable Continuous Glucose Monitors (I-CGM). Check a diagnosis for 0446T.

First covered codes: E08.00 Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC); E08.01 Diabetes mellitus due to underlying condition with hyperosmolarity with coma; E08.10 Diabetes mellitus due to underlying condition with ketoacidosis without coma; E08.11 Diabetes mellitus due to underlying condition with ketoacidosis with coma; E08.21 Diabetes mellitus due to underlying condition with diabetic nephropathy; E08.22 Diabetes mellitus due to underlying condition with diabetic chronic kidney disease; …

A58213: Billing and Coding: Implantable Continuous Glucose Monitors (I-CGM)

Billing and Coding, effective 2026-09-10 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

373 covered ICD-10-CM codes; 3 procedure codes: 0446T, 0447T, 0448T. Local policy: L35490 Category III Codes, L38686 Implantable Continuous Glucose Monitors (I-CGM). Check a diagnosis for 0446T.

First covered codes: E08.00 Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC); E08.01 Diabetes mellitus due to underlying condition with hyperosmolarity with coma; E08.10 Diabetes mellitus due to underlying condition with ketoacidosis without coma; E08.11 Diabetes mellitus due to underlying condition with ketoacidosis with coma; E08.21 Diabetes mellitus due to underlying condition with diabetic nephropathy; E08.22 Diabetes mellitus due to underlying condition with diabetic chronic kidney disease; …

Revision history

02/2005 - Added reference to screening benefits. Effective date 1/01/05. Implementation date 3/11/05. ( TN 28 ) (CR 3690)

07/2004 - Published NCD in NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.20

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.20

What does NCD 190.20 cover?

Blood glucose values are often necessary for the management of patients with diabetes mellitus, where hyperglycemia and hypoglycemia are often present. They are also critical in the determination of control of blood glucose levels in the patient with impaired fasting glucose (FPG 110-125 mg/dL), the patient with insulin resistance syndrome and/or carbohydrate intolerance… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.20 take effect?

The current version (2) is effective 01/01/2005, implemented 03/11/2005, published in transmittal 28. CMS lists 2 versions of this NCD.

Does a Local Coverage Determination override NCD 190.20?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.20?

The October 2026 laboratory NCD edit list contains 4,634 ICD-10-CM codes that support blood glucose testing (for example A15.0 Tuberculosis of lung; A15.5 Tuberculosis of larynx, trachea and bronchus; A22.1 Pulmonary anthrax) and 466 codes that deny. The list applies to 82947, 82948, 82962.

How often does the lab NCD code list for 190.20 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.